1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Nasopharyngitis (Common Cold) - Pipeline Review, H1 2016

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 45 pages

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Pipeline Review, H1 2016’, provides an overview of the Nasopharyngitis (Common Cold) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
- The report reviews pipeline therapeutics for Nasopharyngitis (Common Cold) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nasopharyngitis (Common Cold) therapeutics and enlists all their major and minor projects
- The report assesses Nasopharyngitis (Common Cold) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nasopharyngitis (Common Cold) Overview 6
Therapeutics Development 7
Pipeline Products for Nasopharyngitis (Common Cold) - Overview 7
Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis 8
Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies 9
Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes 10
Nasopharyngitis (Common Cold) - Pipeline Products Glance 11
Early Stage Products 11
Unknown Stage Products 12
Nasopharyngitis (Common Cold) - Products under Development by Companies 13
Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes 14
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development 15
Charleston Laboratories, Inc. 15
Cocrystal Pharma, Inc. 16
Orbis Biosciences, Inc. 17
Vernalis Plc 18
Nasopharyngitis (Common Cold) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
CCP-05 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
CCP-06 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
CCP-07 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CCP-08 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
CLAT-313 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
guaifenesin ER - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Nasopharyngitis (Common Cold) - Recent Pipeline Updates 39
Nasopharyngitis (Common Cold) - Dormant Projects 40
Nasopharyngitis (Common Cold) - Discontinued Products 41
Nasopharyngitis (Common Cold) - Product Development Milestones 42
Featured News and Press Releases 42
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study 42
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Anti-tussive With a Popular Anti-Histamine 42
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 43
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H1 2016 7
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Comparative Analysis by Unknown Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories, Inc., H1 2016 15
Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H1 2016 16
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences, Inc., H1 2016 17
Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Assessment by Combination Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Nasopharyngitis (Common Cold) Therapeutics - Recent Pipeline Updates, H1 2016 39
Nasopharyngitis (Common Cold) - Dormant Projects, H1 2016 40
Nasopharyngitis (Common Cold) - Discontinued Products, H1 2016 41

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H1 2016 7
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...

Rabies - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.